PATIENT SNAPSHOT

40 YEAR-OLD MALE

CHIEF COMPLAINTS

  • Headache
  • Blurring of vision

HISTORY OF PRESENTING ILLNESS

  • Headache — insidious onset, gradually progressive over several months; dull-aching and holocranial in character, more pronounced in the early morning hours; partial relief with over-the-counter analgesics.
  • Visual disturbance — gradual, bilateral blurring of vision with peripheral field involvement noticed by the patient (“bumping into people or objects on either side”), progressively worsening and prompting the current hospital visit.
  • No history of head trauma, seizures, vomiting, or loss of consciousness at presentation.

MASS-EFFECT SCREEN

  • Diplopia — none reported
  • Vomiting — absent, no projectile vomiting
  • Seizures or focal weakness — none
  • No early-morning worsening beyond the headache itself

ENDOCRINE SCREEN

  • Galactorrhea / gynecomastia — absent
  • Libido / erectile function — no change reported
  • Polyuria / polydipsia — absent
  • Acral or facial coarsening (acromegaly) — none noted
  • Weight gain, easy bruising, proximal weakness (Cushing’s) — none noted

Note:

No significant past medical or surgical history. No family history of pituitary or other endocrine disease.

Examination

Finding

General survey

Conscious, oriented; vitals stable; no pallor or icterus

Visual acuity

Mildly reduced, bilateral

Visual fields (confrontation / perimetry)

Bitemporal hemianopia — pattern of optic chiasm compression

Fundus examination

Bilateral optic disc pallor

Cranial nerves III, IV, VI

Grossly intact; no ptosis or diplopia

Motor, sensory, cerebellar exam

Unremarkable

General stigmata

No features of acromegaly, Cushing’s syndrome, or hypothyroidism

Differential Diagnosis

Given the patient’s age and the bitemporal-hemianopia pattern, sellar / parasellar masses were the leading clinical differentials, ranked as follows:

  1. Pituitary macroadenoma — most likely, given the patient’s age and the chiasmal compression pattern on examination.
  2. Craniopharyngioma
  3. Suprasellar / tuberculum sellae meningioma
  4. Rathke’s cleft cyst
  5. Optic or hypothalamic glioma — less likely at this age.
  6. Sellar metastasis — less likely, no known primary malignancy.
 
 

LABORATORY — HORMONAL PROFILE

  • CBC, renal & liver function (baseline)
  • Serum prolactin
  • Growth hormone / IGF-1
  • 8 AM serum cortisol & ACTH
  • TSH, free T4
  • FSH, LH, testosterone

IMAGING & FUNCTIONAL TESTS

  • Visual field perimetry
  • Contrast-enhanced MRI brain — dedicated pituitary protocol
    • (Investigation of choice for sellar/parasellar masses)

ORONAL T2

AXIAL T2

  • A well-defined, heterogeneously hyperintense mass is centered in the sellar region.
  • The mass extends superiorly into the suprasellar cistern, abutting and elevating the optic chiasm.
  • Maximum diameter exceeds 1 cm — in keeping with a macroadenoma rather than a microadenoma.
 

Sellar–suprasellar extension

Sagittal sections confirm that the mass extends from the sella into the suprasellar cistern

MRI Brain — Sagittal View

  • Chiasmal involvement

The lesion abuts the floor of the third ventricle and elevates the optic chiasm — explaining the patient’s visual symptoms

  • Posterior extent

No obvious extension into the posterior fossa or brainstem

  • On pre-contrast T1-weighted images, the sellar mass blends with adjacent brain parenchyma and is poorly conspicuous
  • Following contrast administration, the lesion shows distinct heterogeneous enhancement that clearly outlines its margins — confirming a vascularised sellar mass
  • Chiasm relationship

Best demonstrates the relationship of the mass to the optic chiasm above and the cavernous sinuses on either side

  • Gland of origin

The normal pituitary gland is not separately identified, in keeping with an adenoma arising from and replacing the gland

  • Note

For complete vascular and cavernous-sinus characterization, correlate with the formal radiology report

Sellar–suprasellar mass lesion, heterogeneous on T2-weighted images with heterogeneous post-contrast enhancement, causing superior displacement and compression of the optic chiasm — findings consistent with a Pituitary Macroadenoma.

Functional status (secretory vs non-secretory) to be determined by hormonal profile

Sellar–suprasellar mass, > 10 mm, with optic chiasm compression syndrome

PENDING HORMONAL CORRELATION

What Is a Pituitary Macroadenoma?

Definition

  • A benign, monoclonal tumor of the anterior pituitary gland (adenohypophysis).
  • Among the most common intracranial neoplasms — roughly 10–15% of all primary brain tumors.
  • The overwhelming majority occur sporadically; a small subset is associated with MEN type 1 syndrome.

CLASSIFICATION BY SECRETORY ACTIVITY

FUNCTIONING (HORMONE-SECRETING)

  • Prolactinoma (most common)
  • GH-secreting (acromegaly)
  • ACTH-secreting (Cushing’s disease)
  • TSH-secreting (rare)

NON-FUNCTIONING

  • No hormone hypersecretion; the tumor presents because of mass effect alone (headache, visual field loss, hypopituitarism).

 

Mass Effect?

  • Headache
  • Bitemporal visual field loss / blurring (chiasm compression)
  • Cranial nerve III, IV, VI palsy — if cavernous sinus is invaded
  • Hypopituitarism — fatigue, hypogonadism, hypothyroidism

Harmonal Hypersectretion 

  • Galactorrhea, amenorrhea — prolactinoma
  • Acral / facial coarsening, increased shoe or glove size — acromegaly
  • Central obesity, purple striae, easy bruising — Cushing’s disease

1. Evaluate

  • Multidisciplinary work-up — endocrinology, neurosurgery, ophthalmology

2. Classify

  • Complete hormonal profile to identify functioning vs non-functioning tumor

3. Prolactinoma

  • First-line medical therapy with dopamine agonists (cabergoline / bromocriptine); surgery reserved for resistance or intolerance

4. Non-functioning + Mass Effect

  • Trans-sphenoidal endoscopic surgery (first choice); craniotomy if extensive lateral/suprasellar extension

5. GH- / ACTH-secreting

  • Surgery first-line; somatostatin analogues or other medical therapy as adjunct

6. Post-operative Care

  • Hormone replacement for hypopituitarism; monitor for diabetes insipidus

7. Residual / Recurrent Disease

  • Stereotactic radiosurgery or fractionated radiotherapy
  • Visual recovery is generally favorable with timely chiasmal decompression, before chronic optic atrophy sets in
  • Serial MRI surveillance (e.g., 3 months post-operatively, then annually) to detect residual or recurrent tumor
  • Periodic hormonal assessment; lifelong hormone replacement may be required in some patients
  • Overall prognosis is favorable for non-functioning macroadenomas with timely surgical decompression